Retigabine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Retigabine

Examples of brand names: Trobalt [EU; historical, authorisation withdrawn on 19 July 2018]

ATC code: N03AX21

Main use (for orientation): Historical: add-on treatment of drug-resistant focal seizures in adults

Documented research summary

Existing open-label CBD observation: no concentration signal in only 4 people treated with retigabine (p=0.5677); very limited evidential value. No verified clinical pair study for the other cannabinoids.

Uncertainties and limitations

Historical product information from 2013; withdrawn in the EU since 2018. EMA access failed with status 429.

Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.

CL20 methods, Table 2 and discussion read in the locally available PMC full text; initial web PMC access encountered a CAPTCHA.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – clinical signals

Finding ID: B0062

Type of result: No / minor effect under the conditions studied

Observation: No concentration signal; p=0.5677.

Mechanism: PK observation

Study type: Observational study: no signal detected

Context studied: n=4.

Clinical interpretation: Not ruled out

Limitations and uncertainties: Context / limitations of CL20; a lack of statistical significance does not establish equivalence.

Original sources for this finding: Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program [CL20]

References and access status

[BWEB05] Trobalt retigabine Product Information AusPAR

Original source / bibliographic reference

Authors: GlaxoSmithKline Australia / TGA

Year: 2013

Source type: Regulatory product information / SmPC

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CL20] Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program

Original source / bibliographic reference

Authors: Gaston TE; Bebin EM; Cutter GR; Grayson L; Szaflarski JP

Year: 2023

Source type: Open-label longitudinal observational study

DOI: 10.1002/epi4.12815

PMID: 37593907

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility